1.Clinical features, treatment and prognosis analysis of the asymptomatic patients with retinoblastoma
Xiuqian YI ; Xiaoting ZHOU ; Jiang QIAN ; Hui REN ; Kang XUE
Chinese Journal of Ocular Fundus Diseases 2021;37(3):201-205
Objective:To analyze the clinical features, treatment and prognosis of asymptomatic patients with retinoblastoma.Methods:A retrospective series of case study. Eight asymptomatic patients (11 eyes) with the diagnosis of retinoblastoma by screening enrolled in Department of Ophthalmology of The Eye-ENT Hospital of Fudan University from January 2006 to March 2019 were included. There were 6 males and 3 females ranging from 2 days to 20 months, with a median age of 6 months. Five patients were unilateral retinoblastoma while 3 patients were bilateral. Based on the International Classification of Intraocular Retinoblastoma, 4 eyes were stage A, 3 eyes were stage B and 4 eyes were stage C. One patient had family history. Four patients were evaluated the Rb1 mutation. Routine ophthalmic examinations and ultra-wide field fundus imaging were performed on the 16 parents and 3 siblings of the 8 patients. Systemic intravenous chemotherapy was performed using the Carboplatin, Vincristine, Etoposide protocol, intra-arterial chemotherapy using Carboplatin and Melphalan, and local treatment involved cryotherapy and transpupillary thermotherapy. The mean follow-up time is 47.25 months.Results:None of the 8 children had any ocular symptoms. Six patients received intravenous chemotherapy (5-6 times), 1 patient received intra-arterial chemotherapy (3 times), and 1 patient just received local treatment. Among the 11 eyes, 9 eyes were treated with local cryotherapy and 8 eyes were treated with transpupillary thermotherapy. During the follow-up period, 2 patients had new tumor, and the average time was 6.3 months after the last chemotherapy. At the last follow-up, the tumor disappeared in 11 eyes, remained stable in 11 eyes. The eye protection rate was 100% (8/8) for patients without eyeball excision. The best corrected visual acuity was 0.1 for 3 eyes and 1.0 for 5 eyes. Three eyes were not found. One heterozygous mutation of Rb1 gene [1c.35_69del (p.T12fs)] was identified in 1 patient, and the other 3 patients were not detected. One had bilateral bulbar tuberculosis of the 16 parents, 1 had bilateral RB of the 3 siblings. They were the mother and brother of a child with bilateral RB.Conclusions:Fundus screening is helpful for the detection of early RB. The eye protection rate is high and the long-term vision prognosis is good after systemic or topical chemical drugs (IVC, IAC) and ocular topical treatment (cryopreservation and transpupillary thermotherapy).
2.Preparation and Quality Control of Podophyllotoxin-Loaded Solid Lipid Gel
Zhonghong JIANG ; Kang ZENG ; Guofeng LI ; Dongfeng GU ; Fei REN ; Yujie SHI
China Pharmacy 2005;0(16):-
OBJECTIVE: To prepare podophyllotoxin-loaded solid lipid (PPT-SLN) gel and establish its quality control method. METHODS: With stearic acid, stearylamine, soybean lecithin as cosurfactant and PPT as principal agent, PPT-SLN suspension was prepared by the method of emulsion evaporation and solidification at a low temperature, then prepared into PPT-SLN gel with carbomer used as gel matrix. The physicochemical properties of the preparation were investigated, the content and entrapment efficiency of PPT were determinated by high-performance liquid chromatography (HPLC), respectively. The stability of the preparation was investigated as well. RESULTS: PPT-SLN gel appeared as lacte translucent semisolid, with its property and test results all in conformity with the related specification in Chinese Pharmacopoia (2005 edition). The nanoparticles were well-distributed in round or oval shape, with an average particle size of (105.3?34.7) nm, entrapment efficiency of 72.5% and pH value of (7.2?0.3). The preparation was stable within 6 months under room temperature. CONCLUSION: The preparation technology of PPT-SLN gel is feasible and its quality is controlable.
3.Detection of anti-M2 autoantibody using recombinant BCOADC-E2
Yan CHEN ; Ding-Kang YAO ; Ye ZHOU ; Ye ZHU ; Ting-Wang JIANG ; An-Mei DENG ; Ren-Qian ZHONG ;
Chinese Journal of Rheumatology 2003;0(07):-
Objective To detect anti-M_2 autoantibody using recombinant BCOADC-E_2.Methods We purified recombinant BCOADC-E_2 by Ni~(2+)affinity chromatography column and then detect anti-M_2 autoan- tibody in the sera of patients with primary biliary cirrhosis(PBC)by Western blot test(WBT)and enzyme linked immunosorbent assays(ELISA).Results Among 60 sera from PBC patients,33 were positive,all of controls were negative.Conclusion The recombinant BCOADC-E_2 can be used to detect anti-M_2 autoanti- body specifically and sensitively.It is helpful for the diagnosis of PBC.
4.Development and application of ultrasound technology for hyperthermia.
Liang ZHAI ; Fu-cheng SUN ; Ji-wei JIANG ; Xiang-ling XIAO ; Xiao-ping QIAN ; Yi-kang WANG ; Ren-kang YU ; Yong-jiang XU ; Hong-feng ZHANG
Chinese Journal of Medical Instrumentation 2002;26(4):281-280
It has been a long time since ultrasound hyperthermia began to be used in the clinical management of cancers and benign diseases. Numerous biological and clinical investigations have demonstrated that: hyperthermia in the range of 41-45 degrees C can significantly enhance clinical response to radiation therapy and chemotherapy, and high-temperature hyperthermia (greater than 65 degrees C) alone is now being used as an alternative to conventional invasive surgery for selective tissue destruction, causing tumor coagulation and necrosis. As a promising noninvasive and effective local therapy, HIFU has attracted great attention. China is advanced in the clinical applications of HIFU. This article gives an introduction of the development and applications of ultrasound hyperthermia technology, and also provides a general review of a selection of ultrasound hyperthermia systems both in clinical use and under development.
Equipment Design
;
Humans
;
Hyperthermia, Induced
;
instrumentation
;
methods
;
Neoplasms
;
therapy
;
Ultrasonics
;
Ultrasound, High-Intensity Focused, Transrectal
5.Research advances of herpesvirus gB gene and its encoding protein.
Long JIANG ; Hui-juan LIU ; An-chun CHENG ; Ming-shu WANG ; Zheng-li CHEN ; Ren-yong JIA ; De-kang ZHU ; Xiao-yue CHEN
Chinese Journal of Virology 2010;26(5):414-417
Glycoproteins
;
genetics
;
metabolism
;
Herpesviridae
;
genetics
;
metabolism
;
Viral Proteins
;
genetics
;
metabolism
6.Research advancement of calcium phosphate and calcium sulfate scaffolds in bone tissue engineering
Zhida ZHANG ; Xiaobing JIANG ; Gengyang SHEN ; Hui REN ; Zhidong YANG ; Jianchao CUI ; Kang CHEN ; Jingjing TANG ; Ling MO ; Shunxin LIN ; De LIANG
Chinese Journal of Tissue Engineering Research 2016;20(8):1203-1209
BACKGROUND: It is a hotspot that calcium phosphate and calcium sulphate as the main ingredients are combined with one or more other materials to improve or increase the performance of bone tissue engineering scaffolds. OBJECTIVE: To introduce the research advance of these two kinds of scaffolds in bone tissue engineering. METHODS: The articles related to the bone tissue engineering published during January 2000 to June 2015 were retrieved from CNKI and PubMed databases by computer. The key words were “bone tissue engineering, scaffold, calcium phosphate, calcium sulphate, vascularization” in Chinese and English, respectively. ESULTS AND CONCLUSION: Calcium phosphate and calcium sulfate are characterized as having good biocompatibility, biodegradability, osteoconductivity and complete bone substitutability. However, single use of calcium phosphate or calcium sulfate scaffold has certain disadvantages, both of which are difficult to ful y meet the requirements of the bone defect repair. Improvement can be acquired in the mechanical strength, injectability and biodegradability, as wel as drug-loading and pro-angiogenesis of the scaffold in combination with other materials. In the basal and clinical research, we should explore and develop ideal scaffolds in on the basis of therapeutic aim. However, most of the scaffold studies are stil at the extracorporeal and animal experiment stage, and the comparative studies on composite scaffolds and optimal proportion of those composite scaffolds stil need to be further investigated.
7.Biological activities of the coagulation factor VIII, IX in platelet concentrates collected by platelet apheresis during preservation.
Jiang-Cun YANG ; Feng-Qin LI ; Mang-Hui LI ; Jian-Kang REN
Journal of Experimental Hematology 2006;14(1):162-164
The study was to explore the change of coagulation factor VIII and IX activities in the platelet suspension collected by platelet apheresis during storage at 22 degrees C. 18 samples of platelet concentrates were collected by the cs-3000 plus and stored at 22 degrees C and then FVIII: C, FIX: C activities were detected at 0, 12, 24, 48, 72, 96, 120 hours respectively by SYSMEX CA-1500. The results showed that FVIII: C activity was (100.51 + 44.02)% at 0 hour, and then decreased dramatically to 10% - 40% of primary level from 12 to 120 hours, while FIX: C activity was (120.93 +/- 20.50)% at 0 hour and decreased to 10% - 35% of primary level from 24 to 120 hours. In conclusion, FVIII and FIX in the platelet concentrates stored at 22 degrees C could keep their biological activities at physiologically high levels.
Blood Platelets
;
Blood Preservation
;
methods
;
Factor IX
;
metabolism
;
Factor VIII
;
metabolism
;
Humans
;
Platelet Transfusion
;
Plateletpheresis
;
methods
8.Effects of percutaneous coronary intervention on life quality and cardiac events in elderly patients with stable angina caused by chronic coronary total occlusion
Jiang LI ; Wenxian LIU ; Yanlong REN ; Yunpeng KANG
Chinese Journal of Geriatrics 2019;38(2):124-127
Objective To investigate the effects of percutaneous coronary intervention(PCI)on life quality and cardiac events in elderly patients with stable angina owing to chronic coronary total occlusion(CTO).Methods Patients with stable angina due to CTO hospitalized in Beijing Anzhen Hospital from January 2015 to January 2018 were consecutively recruited in this prospective study,and were randomly divided into the combined treatment group(n=44)and the control group (n=43).Patients in the combined treatment group were treated with PCI and optimal medical therapy,and those in the control group were treated with optimal medical therapy alone.Patients followed up for 6 months after treatment.Cardiac function,life quality(Seattle angina questionnaire,SAQ)and adverse cardiovascular events were compared before and after treatment.Results A total of 87 patients were involved,with a mean age of (69.5 ± 7.2) years.Basic characteristics,including age,sex ratio,previous history,left ventricular ejection fraction,coronary artery lesions and SAQ scores,were similar between the groups(P>0.05).After a 6 month post treatment follow up,SAQ scores improved in all patients,compared with those before treatment(P<0.05).Moreover,patients in the combined treatment group had higher SAQ scores on physical limitation(86.3 ± 11.6 vs.76.3 ± 21.3),angina stability(67.3 ±24.5 vs.57.3±21.2)and angina frequency(93.3±4.3 vs.86.4±8.3)than those in the control group (P <0.05).There was no significant difference in major adverse cardiovascular event rate between the groups[18.2%(8 cases) vs.16.3%(7 cases),X2 =0.055,P>0.05].Conclusions Combined with optimal medical therapy,PCI can improve the life quality in elderly patients with stable angina due to CTO,but has no significant influence on the short-term major adverse cardiovascular event rate.
9.Research on the influence of 12-week basic load resistance training on the physical fitness of flight students in an aviation school.
Zhe JI ; Hai-Tao ZHOU ; Zhi-Kang ZOU ; Xian GUO ; Xin ZHANG ; Hui CAO ; Zhi-Dong JIANG ; Xiang REN ; An-Li WANG ; Jian-Min CAO
Chinese Journal of Applied Physiology 2021;37(5):519-522
10.Therapeutic effect of ovarian intra-arterial infusion of GE7-delivery system-mediated HSVl-tk/ganciclovir gene therapy in a rat model of malignant ovarian tumor.
Wei JIANG ; Xiao-xia LIU ; Yu KANG ; Zhi-min SHAO ; Wen-jiang ZHOU ; Jian-ren GU ; Cong-jian XU
Chinese Journal of Oncology 2012;34(4):245-248
OBJECTIVETo observe the gene expression of herpes simplex virus type 1 thymidine kinase (HSVl-tk) in rat malignant ovarian tumor tissues and the therapeutic effect of ganciclovior (GCV) after intra-arterial infusion of HSVl-tk gene therapy mediated by GE7-delivery system.
METHODSA GE7-polylysine/pCMV-HSV1-tk/polylysine-HA20 4-element complex was constructed. Eighteen rats with DMBA-induced ovarian tumor were divided into 3 groups as Atk, ANS and Vtk groups. The 4-element complex GE7-polylysine/pCMV-HSV1-tk/polylysine-HA20 was injected via the ovarian artery into the rats of Atk group, saline buffer was injected in the ANS groups, and the 4-element complex was injected via the tail vein into the rats of Vtk group. All rats received intraperitoneal injection of GCV in a dose of 50 mg/kg daily for 10 days. The rats were sacrificed 3 days after the final dose of GCV, and the tumor weight was measured and tumor growth inhibition rate was calculated. Flow cytometry was used to assess the cell cycle and apoptosis.
RESULTSThe tumor weight in the rats of Atk group was (4.77 ± 2.31) g, significantly lower than that of ANS group [(14.66 ± 6.26) g, P < 0.01] and Vtk group [(17.53 ± 7.19) g, P < 0.01]. The tumor growth inhibition rate of the Atk group was 67.5%, while that of Vtk group was -19.6%. The flow cytometry showed that S-phase tumor cells in the Atk group were (54.32 ± 9.65)%, significantly higher than that in the ANS (27.43 ± 9.22)% and (30.16 ± 11.57)% in the Vtk group (both P < 0.01). The tumor cell apoptosis rate in the Atk group was (39.15 ± 12.16)%, significantly higher than that in the ANS group [(11.86 ± 5.28)%, P < 0.01] and Vtk group [(14.32 ± 6.43)%, P < 0.01].
CONCLUSIONHSV1-tk/GCV gene therapy system mediated by GE7 non-viral delivery system via ovarian arterial infusion effectively causes cell cycle arrest at S phase and enhances cell apoptosis, therefore, exerts an inhibitory effect on tumor growth.
9,10-Dimethyl-1,2-benzanthracene ; Adenocarcinoma ; chemically induced ; pathology ; therapy ; Animals ; Antiviral Agents ; pharmacology ; Apoptosis ; drug effects ; Cell Cycle ; drug effects ; Female ; Ganciclovir ; pharmacology ; Gene Transfer Techniques ; Genetic Therapy ; Herpesvirus 1, Human ; genetics ; metabolism ; Infusions, Intra-Arterial ; Ovarian Neoplasms ; chemically induced ; pathology ; therapy ; Random Allocation ; Rats ; Rats, Wistar ; Thymidine Kinase ; genetics ; metabolism